• news.cision.com/
  • Wacker-Kemi AB/
  • US-Based Genopis – WACKER’s Recently Acquired Plasmid DNA Contract Manufacturer – Is Renamed Wacker Biotech US

US-Based Genopis – WACKER’s Recently Acquired Plasmid DNA Contract Manufacturer – Is Renamed Wacker Biotech US

Report this content

Munich / San Diego, March 19, 2021 – Wacker Biotech US Inc. is the new name of Genopis Inc., the plasmid DNA manufacturer based in San Diego, USA, that WACKER acquired in February. The acquisition concerns a plasmid DNA (pDNA) CDMO (Contract Development and Manufacturing Organization) site and its associated business.

“Changing the name to Wacker Biotech US is the next step in integrating Genopis into the WACKER Group. What’s more, the names of our biotech subsidiaries are now uniform. Together, Wacker Biotech GmbH, Wacker Biotech B.V. and Wacker Biotech US Inc. form a strong partner when it comes to the contract manufacturing of biopharmaceuticals,” explains Guido Seidel, vice president of WACKER’s Biopharma activities and responsible for global biopharmaceutical business. By providing expertise in pDNA technology, Wacker Biotech US Inc. thus expands WACKER’s existing portfolio and creates the basis for further growth in the Biopharma segment. At the same time, Wacker Biotech US Inc. gives WACKER a local presence in the all-important US market for biopharmaceuticals.

Munich-based chemical company WACKER acquired 100% of the shares in pharmaceutical contract manufacturer Genopis Inc. from Helixmith Co Ltd, Seoul (South Korea) and Medivate Partners LLC, Seoul (South Korea) in February. The signing of the related agreement was followed by the successful closing in late February and, now, the acquisition’s new name: Wacker Biotech US Inc. The approximately 40 employees at the company, which was founded in 2018, have extensive experience in the production of pDNA according to “Good Manufacturing Practice” (GMP) quality guidelines. pDNA can be used either directly for nucleic acid-based gene therapies and for vaccines or as a starting point for such innovative therapeutic agents, for example to manufacture messenger RNA (mRNA). Among other things, mRNA is the basis of innovative SARS-CoV-2 vaccines approved in recent months.


About Wacker Biotech

Wacker Biotech GmbH, Wacker Biotech B.V. and Wacker Biotech US Inc. are full-service contract manufacturers of therapeutic proteins, live microbial products (LMPs), vaccines based on microbial systems, and of plasmid DNA. Wacker Biotech’s portfolio extends from strain/process development and analytical testing through to production for clinical and commercial applications. Wacker Biotech maintains three GMP-compliant (Good Manufacturing Practice), FDA- and EMA-certified production plants at its Jena and Halle sites in Germany and in Amsterdam in the Netherlands. The company’s most recent acquisition is its San Diego site (Wacker Biotech US Inc.), added in February 2021. For more information, visit: www.wacker.com/biologics

For further information, please contact:
Wacker Chemie AG
Media Relations & Information
Manuela Dollinger
Tel. +49 89 6279-1629

Företaget i överblick: WACKER är en globalt verksam kemikoncern med cirka 14.300 anställda och en årsomsättning på cirka 4,69 miljarder € (2020). WACKER har 26 produktionsanläggningar, 23 technical competence centers och 52 försäljningskontor över hela världen.



Silikonoljor, silikonemulsioner, silikongummi och silikonhartser, silaner, pyrogena kiselsyror, termoplastiska silikonelastomerer



Polyvinylacetat och vinylacetat ko/ter-polymerer i form av dispersionspulver, dispersioner, fasthartser och lösningar



Bioteknologiska produkter såsom cyklodextriner, cysteiner och biologiska produkter liksom finkemikalier och PVAc fasta hartser



Polysilicium för halvledar- och fotovoltaikindustrin



Dokument & länkar